HK1115801A1 - Gastroresistant pharmaceutical formulations containing rifaximin - Google Patents

Gastroresistant pharmaceutical formulations containing rifaximin

Info

Publication number
HK1115801A1
HK1115801A1 HK08106217.6A HK08106217A HK1115801A1 HK 1115801 A1 HK1115801 A1 HK 1115801A1 HK 08106217 A HK08106217 A HK 08106217A HK 1115801 A1 HK1115801 A1 HK 1115801A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical formulations
formulations containing
containing rifaximin
gastroresistant pharmaceutical
gastroresistant
Prior art date
Application number
HK08106217.6A
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Ernesto Palazzini
Villiam Zamboni
Maria Rosaria Pantaleo
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of HK1115801A1 publication Critical patent/HK1115801A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK08106217.6A 2005-03-07 2008-06-04 Gastroresistant pharmaceutical formulations containing rifaximin HK1115801A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000123A ITBO20050123A1 (it) 2005-03-07 2005-03-07 Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
PCT/EP2006/002022 WO2006094737A2 (en) 2005-03-07 2006-03-06 Gastroresistant pharmaceutical formulations containing rifaximin

Publications (1)

Publication Number Publication Date
HK1115801A1 true HK1115801A1 (en) 2008-12-12

Family

ID=36694343

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106217.6A HK1115801A1 (en) 2005-03-07 2008-06-04 Gastroresistant pharmaceutical formulations containing rifaximin

Country Status (30)

Country Link
US (5) US8568782B2 (hr)
EP (1) EP1874273B1 (hr)
JP (1) JP4827915B2 (hr)
KR (1) KR101157220B1 (hr)
CN (1) CN101137350B (hr)
AU (1) AU2006222206B2 (hr)
BR (1) BRPI0608853B8 (hr)
CA (1) CA2595033C (hr)
CY (1) CY1114132T1 (hr)
DK (1) DK1874273T3 (hr)
ES (1) ES2398564T3 (hr)
HK (1) HK1115801A1 (hr)
HR (1) HRP20070432B1 (hr)
IL (1) IL184695A (hr)
IT (1) ITBO20050123A1 (hr)
MA (1) MA29346B1 (hr)
MD (1) MD4180C1 (hr)
ME (2) MEP31108A (hr)
MX (1) MX2007010889A (hr)
NO (1) NO340155B1 (hr)
NZ (1) NZ556740A (hr)
PL (1) PL1874273T3 (hr)
PT (1) PT1874273E (hr)
RS (1) RS52891B (hr)
RU (1) RU2403015C2 (hr)
SI (1) SI1874273T1 (hr)
TN (1) TNSN07290A1 (hr)
UA (1) UA90881C2 (hr)
WO (1) WO2006094737A2 (hr)
ZA (1) ZA200707396B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
ES2389358T5 (es) * 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
WO2009008006A2 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP2011500552A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
NZ587099A (en) 2008-02-25 2012-08-31 Salix Pharmaceuticals Ltd Forms of rifaximin and uses thereof
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
MX2010009197A (es) * 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
MX345697B (es) 2010-07-12 2017-02-13 Salix Pharmaceuticals Ltd Formulaciones de rifaximina y usos de las mismas.
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
EP2616044A1 (en) * 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
US9668977B2 (en) 2011-06-17 2017-06-06 Evonik Röhm Gmbh Coating composition suitable for pharmaceutical or nutraceutical dosage forms
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) * 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9956310B2 (en) 2012-07-18 2018-05-01 Jeannette Martello Time indicator tampon
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen
MX2015014307A (es) * 2013-04-12 2015-12-08 Alfa Wassermann Spa Administracion de farmacos antiinflamatorios no esteroidales y composiciones, metodos y sistemas relacionados.
CN103340856A (zh) * 2013-07-09 2013-10-09 荣港生技医药科技（北京）有限公司 一种利福昔明药物组合物及其制备方法
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
ES2810010T3 (es) 2014-05-12 2021-03-08 Alfasigma Spa Preparación y uso de la forma cristalina tau de rifaximina solvatada con DEGME
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
CR20180152A (es) 2015-08-12 2018-08-09 Incyte Corp Sales de un inhibidor de lsd1
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
WO2017162725A1 (en) * 2016-03-24 2017-09-28 Sandoz Ag Pharmaceutical composition containing rifaximin alpha & delta
AU2017237469B2 (en) * 2016-03-24 2018-06-28 Sandoz Ag Storage stable composition comprising rifaximin alpha
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ，インコーポレーテッド リファキシミンの固体分散体の形態
MX2018010065A (es) 2017-04-26 2019-02-07 Sandoz Ag Forma de dosificacion oral que comprende rifaximina en forma beta.
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
CA3151010A1 (en) * 2019-09-24 2021-04-01 Arturo J. Angel Rifaximin liquid formulations
CA3184054A1 (en) * 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US11944633B2 (en) 2022-02-17 2024-04-02 Woolsey Pharmaceuticals, Inc. Oral formulations of fasudil with ion exchange resin

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH547854A (de) 1969-05-30 1974-04-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von antibiotika.
US4206677A (en) 1978-07-17 1980-06-10 Teledyne Industries, Inc. Pedal actuator for electronic player piano
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
US5356625A (en) * 1986-08-28 1994-10-18 Enzacor Properties Limited Microgranular preparation useful in the delivery of biologically active materials to the intestinal regions of animals
GB2253346A (en) * 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) * 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US5549911A (en) * 1994-01-14 1996-08-27 Laboratoires Des Produits Ethiques Ethypharm Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
US5592021A (en) * 1995-04-26 1997-01-07 Martin Marietta Corporation Clamp for securing a power device to a heatsink
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
ATE430477T1 (de) 1996-10-16 2009-05-15 Napo Pharmaceuticals Inc Enteral-formulierungen von proanthocyanidzusammensetzungen gegen diarrhöe
IT1290679B1 (it) 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US20030157174A1 (en) * 2000-03-23 2003-08-21 Takayuki Tsukuda Enteric granular preparations of hardly water soluble drugs characterized by containing water-repellent component
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
JP4019374B2 (ja) * 2001-07-27 2007-12-12 アステラス製薬株式会社 口腔内速崩壊錠用徐放性微粒子含有組成物およびその製造法
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003244840C1 (en) * 2002-07-05 2010-03-04 Temrel Limited Controlled release composition
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US20080262024A1 (en) 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050196418A1 (en) 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
EP1778195A2 (en) 2004-07-16 2007-05-02 Cipla Limited Anti-histaminic composition
US20060210492A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
SI1698630T1 (sl) 2005-03-03 2015-01-30 Alfa Wassermann S.P.A. Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ES2747259T3 (es) 2006-03-09 2020-03-10 Salix Pharmaceuticals Inc Preparación anti-disfunción rectal de rifaximina
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
AU2007248183B2 (en) 2006-05-01 2013-08-01 Napo Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory bowel disease, familial adenomatous polyposis and colon cancer
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ， インコーポレイテッド 放射線直腸ｓ状結腸炎を処置するための組成物および方法
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
ES2389358T5 (es) 2007-07-06 2016-01-19 Lupin Ltd. Composiciones farmacéuticas de rifaximina
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
EP2201372A4 (en) 2007-10-17 2010-11-10 Salix Pharmaceuticals Ltd NEW THERAPEUTIC TARGETS FOR INTESTINAL DISEASE
MX2010009197A (es) 2008-02-26 2010-11-22 Salix Pharmaceuticals Ltd Metodos para tratar padecimientos del intestino.
US20110065741A1 (en) 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
CA2723752A1 (en) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
PT2327407E (pt) 2008-09-26 2014-09-10 Aska Pharm Co Ltd Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20100317681A1 (en) 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2010044093A1 (en) 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
IT1397617B1 (it) 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
WO2010148040A1 (en) 2009-06-15 2010-12-23 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
WO2011050397A1 (en) 2009-10-26 2011-05-05 Borody Thomas J Novel enteric combination therapy
ES2712080T3 (es) 2009-10-27 2019-05-09 Lupin Ltd Dispersión sólida de rifaximina
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
JP2013511569A (ja) 2009-11-23 2013-04-04 シプラ・リミテッド 局所用泡沫組成物
CN101773465B (zh) 2010-01-19 2012-11-07 南京泛太化工医药研究所 以氨基酸为稳定剂的聚合物胶束载药系统
JP5896380B2 (ja) 2010-02-18 2016-03-30 サリックス ファーマスーティカルズ，リミテッド 感染症を治療するための方法
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CA2800235C (en) 2010-03-10 2018-10-16 Lupin Limited Rifaximin ready-to-use suspension
MX345697B (es) 2010-07-12 2017-02-13 Salix Pharmaceuticals Ltd Formulaciones de rifaximina y usos de las mismas.
EP2616044A1 (en) 2010-09-13 2013-07-24 Cilpa Limited Pharmaceutical composition
IT1403847B1 (it) 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
US20130184302A1 (en) 2011-11-02 2013-07-18 Enoch Bortey Methods for treating irritable bowel syndrome (ibs) and infections
MX2015015700A (es) 2013-05-17 2016-06-02 Salix Pharmaceuticals Inc Metodos para usar rifaximina en exploraciones de tomografia por emision de positrones (pet).

Also Published As

Publication number Publication date
CA2595033C (en) 2013-05-28
IL184695A0 (en) 2007-12-03
CN101137350A (zh) 2008-03-05
RU2007136428A (ru) 2009-04-20
PT1874273E (pt) 2013-03-11
RS20070365A (en) 2009-01-22
DK1874273T3 (da) 2013-01-28
MD4180C1 (ro) 2013-03-31
NZ556740A (en) 2010-07-30
US8568782B2 (en) 2013-10-29
SI1874273T1 (sl) 2013-04-30
MX2007010889A (es) 2007-11-23
UA90881C2 (uk) 2010-06-10
WO2006094737A8 (en) 2007-11-15
MD20070267A (en) 2008-06-30
IL184695A (en) 2012-12-31
TNSN07290A1 (en) 2008-12-31
CY1114132T1 (el) 2016-07-27
CN101137350B (zh) 2013-09-11
CA2595033A1 (en) 2006-09-14
BRPI0608853B1 (pt) 2020-05-19
RS52891B (en) 2014-02-28
BRPI0608853B8 (pt) 2021-05-25
AU2006222206A1 (en) 2006-09-14
JP4827915B2 (ja) 2011-11-30
US20140112987A1 (en) 2014-04-24
HRP20070432A2 (hr) 2007-11-30
US20140186450A1 (en) 2014-07-03
ES2398564T3 (es) 2013-03-20
KR20070117616A (ko) 2007-12-12
NO20075046L (no) 2007-12-05
ME00199B (me) 2011-02-10
BRPI0608853A2 (pt) 2010-02-02
MD4180B2 (en) 2012-08-31
HRP20070432B1 (hr) 2015-02-13
MEP31108A (hr) 2010-10-10
NO340155B1 (no) 2017-03-13
RU2403015C2 (ru) 2010-11-10
JP2008531743A (ja) 2008-08-14
MA29346B1 (fr) 2008-03-03
PL1874273T3 (pl) 2013-04-30
KR101157220B1 (ko) 2012-07-09
EP1874273A2 (en) 2008-01-09
ITBO20050123A1 (it) 2005-06-06
US10285944B2 (en) 2019-05-14
US20200000726A1 (en) 2020-01-02
EP1874273B1 (en) 2013-01-02
WO2006094737A3 (en) 2007-02-15
ZA200707396B (en) 2009-08-26
BRPI0608853A8 (pt) 2017-12-26
AU2006222206B2 (en) 2010-07-08
US20100330129A1 (en) 2010-12-30
WO2006094737A2 (en) 2006-09-14
US20090011020A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
HK1115801A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
GB2424581B (en) Formulations
IL177566A0 (en) Pharmaceutical formulations
EP1981547A4 (en) STABLE THERAPEUTIC FORMULATIONS
GB0501999D0 (en) Pharmaceutical compounds
GB0520657D0 (en) Pharmaceutical compounds
GB0520656D0 (en) Pharmaceutical compounds
EP1909584A4 (en) PRENYLFLAVONOID FORMULATIONS
GB0426301D0 (en) Pharmaceutical formulations
IL187748A0 (en) Pharmaceutical compositions containing misoprostal
IL185773A0 (en) Formulations
EP1951693A4 (en) SOLID FORMULATIONS
GB0512643D0 (en) Pharmaceutical compounds
EP1853238A4 (en) PHARMACEUTICAL FORMULATIONS WITH 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN
GB0416397D0 (en) Pharmaceutical formulations
ZA200705612B (en) Pharmaceutical compounds
GB0501475D0 (en) Pharmaceutical compounds
GB0408070D0 (en) Pharmaceutical formulations
GB0428010D0 (en) Pharmaceutical formulations
GB0408076D0 (en) Pharmaceutical formulations
GB0515937D0 (en) Pharmaceutical formulation
GB0526322D0 (en) Formulations
GB0518878D0 (en) Formulations
GB0520388D0 (en) Formulations
GB0522917D0 (en) Formulations